跳至主要内容
临床试验/NCT00542126
NCT00542126Unknown不适用

Luteal-Phase GnRH Agonist Administration in Frozen-Thawed IVF Embryo Transfer Cycles

Shaare Zedek Medical Center1 个研究点 分布在 1 个国家开始时间: 2007年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
试验地点
1
主要终点
pregnancy and delivery rates

研究概览

简要总结

Supraphysiological hormonal stimulation enables collecting many oocytes in an In-Vitro Fertilization treatment, but may have a negative effect on uterine function and contribute the fact that the majority of preembryos placed in the uterus fail to implant.

Several medical agents were shown to be beneficial when given in the luteal phase of an IVF cycle, but the optimal regimen has not been yet determined. In 2006, a European group reported that addition of GnRH analog (Decapeptyl) as luteal support in IVF cycle significantly improved pregnancy and delivery rates. It is not known whether this positive effect influences the corpus luteum, embryo or the uterus. The researchers sought to evaluate the effect of GnRH administration as luteal support in frozen-thaws IVF cycle.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 38 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • IVF patients transfer of a minimum of two medium-quality thawed embryos in IVF

排除标准

  • Two or more fresh IVF embryo transfer or three or more thawed embryos transfer with no pregnancy.
  • maximal endometrial thickness < 6 mm or intracavitary fluid at the time of embryo transfer on previous cycles
  • Untreated hydrosalpinges
  • intracavitary mass
  • submucous myoma
  • known allergy to one of medical agents used in the study

研究组 & 干预措施

1

Active Comparator

GnRH analog administration following embryo transfer

干预措施: Decapeptyl 0.1 mg after embryo transfer (Drug)

结局指标

主要结局

pregnancy and delivery rates

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验